Click on image to view larger version.

Figure 6 Akt phosphorylation with atorvastatin after 10 min of reperfusion: the effect of wortmannin and the absence of eNOS. Administration of atorvastatin to wild-type and KO hearts resulted in a robust increase in phosphorylation of Akt, although no cardioprotection is seen in eNOS KO hearts (**p < 0.001 vs. control hearts). The administration of the PI3K inhibitor, wortmannin, significantly reduced Akt phosphorylation compared with both control and atorvastatin-treated hearts (p < 0.01 vs. both control and atorvastatin groups).